Teen brain scans reveal what happens when cannabis stops
NCT ID NCT06124846
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the brains of teens (ages 15-18) with cannabis use disorder change when they stop using cannabis for 6 weeks. Researchers will use MRI scans to measure brain activity related to reward and impulse control. Some teens will be paid to stay cannabis-free, while others will not be asked to stop. The goal is to learn more about how abstinence affects the brain, not to test a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 64 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male and female adolescents between the ages of 15 and 18 (inclusive). * Have a parent or legal guardian who is able and willing to provide written informed consent. * Competent and willing to provide written informed assent (participants \<18) or consent (participants=18). * Native English speaker. * Have a parent or legal guardian who is fluent in English. * Able to commit to 9 study visits in approximately 60 days (6 weeks). * Able to safely participate in the protocol and appropriate for outpatient level of care, in the opinion of the PI. * No active psychosis or current use of antipsychotic medications. * Participants taking psychotropic medications will be included if the medications have been stable for 6 weeks and are expected to remain stable for the duration of their study participation (i.e., through the third MRI). * For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on average in the past two months and meet DSM-V cannabis use disorder (CUD; at least Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive qualitative urine toxicology test at baseline for THC. No immediate plan to discontinue cannabis use. * For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine toxicology test at baseline for THC. No immediate plans to begin cannabis use. * For optional components (A: daily remote assessments during and/or (B) after treatment period): access to a personal device (e.g., smartphone or computer) on which to complete daily remote assessments. Exclusion Criteria: * Past twelve-month history of substance use disorders (except for Cannabis Use Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics interview at baseline. * Contraindications for MRI (ascertained via participant and parent report), including but not limited to: 1. Metal implants such as surgical clips or pacemakers, or history of working with metal, unless the possibility of a metal fragment can be ruled out by recent orbital scans. 2. Prior head trauma with neurological sequelae. 3. Claustrophobia. 4. Weight incompatible with MRI safety. 5. Pregnancy. * Previous or current diagnosis of psychosis, cognitive disability, or bipolar disorder. * Active suicidality. * Taking a psychotropic medication that has not reached stability criterion (same medication type and dose for 6 weeks with no planned changes over the study period). * Any other medical or psychiatric condition deemed serious or contraindicated for any study procedures by Dr. Tervo-Clemmens.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55414, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website help people cut back on cannabis?
- Brain scans probe why cannabis hits men and women differently
- Can rewards and remote coaching help people cut back on cannabis?
- Can a phone app curb cannabis use in early psychosis?
- Can a sleep pill curb cannabis addiction?
- Pharmacies vs. street: does regulated cannabis improve health?